The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Chiara Molinelli, Lucia Del Mastro, Eva Blondeaux et al.|European Journal of Cancer|2024

Cited by 15